{"analyses":[{"ciLowerLimit":"0.21","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.31","estimateComment":"Reference arm = Chemotherapy arm","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.18","paramType":"Hazard Ratio (HR)","paramValue":"0.52","statisticalMethod":"Gray's test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.3","upperLimit":"50.5","value":"31.6"},{"groupId":"OG001","lowerLimit":"6.3","upperLimit":"34.1","value":"17.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"description":"Neurocognitive failure is defined as cognitive failure on two or more of the following tests: Hopkins Verbal Learning Test - Revised (HVLT-R) Free Recall, HVLT-R Delayed Recall, HVLT-R Delayed Recognition, Trail Making Test Part A, Trail Making Test Part B, and Controlled Oral Word Association. Cognitive failure for each test is defined as a change from baseline in raw score (post baseline score - baseline score) at or exceeding the minimally important difference reported in the literature \\[determined by the reliable change index (RCI) method\\] of -5, -3, -2,12, 26, and -12, respectively, indicating a worsening of neurocognitive function. Time to neurocognitive failure is defined as time from randomization to date of first failure, last known follow-up (censored), or death without failure (competing risk). Failure rates are estimated using the cumulative incidence method and the distributions of failure times are compared between the arms. Two-year estimates are provided here.","dispersionType":"95% Confidence Interval","groups":[{"description":"Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 3-5 weeks later by two 28-day cycles of cytarabine.","id":"OG000","title":"Chemotherapy"},{"description":"Rituximab, methotrexate, procarbazine for four 28-day cycles with vincristine for the first two cycles, followed 2-5 weeks later by 3 weeks of low-dose whole-brain radiotherapy (WBRT), followed 3-5 weeks later by two 28-day cycles of cytarabine.","id":"OG001","title":"Chemotherapy + Low-Dose WBRT"}],"paramType":"NUMBER","populationDescription":"Eligible, consented to neurocognitive function study component and has at least two completed neurocognitive tests at baseline and at least one post baseline visit.","reportingStatus":"POSTED","timeFrame":"Neurocognitive function tests were administered at baseline, after cycle 4 of treatment (4 months), then every six months after end of treatment (7 months) for five years. Two-year rates are provided here.","title":"Percentage of Participants With Neurocognitive Failure","type":"SECONDARY","unitOfMeasure":"percentage of participants"}